Genetic modifiers of cystic fibrosis-related diabetes

Diabetes

Volumn 62, Issue 10, 2013, Pages 3627-3635

  Blackman, Scott M ^a   Commander, Clayton W ^b   Watson, Christopher ^a   Arcara, Kristin M ^a   Strug, Lisa J ^c,d   Stonebraker, Jaclyn R ^b   Wright, Fred A ^b   Rommens, Johanna M ^d,e   Sun, Lei ^c   Pace, Rhonda G ^b   Norris, Sarah A ^b   Durie, Peter R ^c,d   Drumm, Mitchell L ^f   Knowles, Michael R ^b   Cutting, Garry R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR 7 LIKE 2; ANTIPORTER; CDKAL1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 5; IGF2BP2 PROTEIN, HUMAN; RNA BINDING PROTEIN; SLC26A9 PROTEIN, HUMAN;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIER GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC26A9 GE; ADOLESCENT; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS; RISK; TWINS; UNITED STATES;

ADOLESCENT; ADULT; ANTIPORTERS; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA-BINDING PROTEINS; UNITED STATES;

EID: 84891361596     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0510     Document Type: Article

References (52)

1. Moran A, Becker D, Casella SJ, et al.; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33:2677-2683
2. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988;112:373-377
3. Hameed S, Jaffé A, Verge CF. Cystic fibrosis related diabetes (CFRD)-the end stage of progressive insulin deficiency. Pediatr Pulmonol 2011;46:747-760
4. Lanng S, Thorsteinsson B, Erichsen G, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child 1991;66:612-616
5. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-687
6. Minicucci L, Lorini R, Giannattasio A, et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr 2007;96:736-739
7. Blackman SM, Hsu S, Vanscoy LL, et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009;94:1302-1309
8. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab 1996;81:1267-1272
9. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629-3643
10. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44:981-990
11. Blackman SM, Hsu S, Ritter SE, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009;52:1858-1865
12. Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011;43:539-546
13. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007;175:1036-1043
14. Drumm ML, Konstan MW, Schluchter MD, et al.; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453
15. Bartlett JR, Friedman KJ, Ling SC, et al.; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-1083
16. Sun L, Rommens JM, Corvol H, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 2012;44:562-569
17. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006;131:1030-1039
18. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:816-834
19. Abecasis GR, Altshuler D, Auton A, et al.; 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing [corrected in Nature 2011;473:544]. Nature 2010;467:1061-1073
20. Li W, Sun L, Corey M, et al. Understanding the population structure of North American patients with cystic fibrosis. Clin Genet 2011;79:136-146
21. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in metaanalysis: multivariate approach and meta-regression. Stat Med 2002;21: 589-624
22. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
24. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575
25. Gaulton KJ, Nammo T, Pasquali L, et al. A map of open chromatin in human pancreatic islets. Nat Genet 2010;42:255-259
26. ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011;9:e1001046
27. Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol 2009;133:421-438
28. Ko SB, Zeng W, Dorwart MR, et al. Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol 2004;6:343-350
29. Chang MH, Plata C, Sindic A, et al. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain. J Biol Chem 2009;284:28306-28318
30. Avella M, Loriol C, Boulukos K, Borgese F, Ehrenfeld J. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J Cell Physiol 2011;226:212-223
31. Ousingsawat J, Schreiber R, Kunzelmann K. Differential contribution of SLC26A9 to Cl(2) conductance in polarized and non-polarized epithelial cells. J Cell Physiol 2012;227:2323-2329
32. Stalvey MS, Muller C, Schatz DA, et al. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes 2006;55:1939-1945
33. Polychronakos C. Early onset diabetes mellitus. Tip or iceberg? Pediatr Diabetes 2004;5:171-173
34. Boom A, Lybaert P, Pollet JF, et al. Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas. Endocrine 2007;32:197-205
35. Lohi H, Kujala M, Makela S, et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9. J Biol Chem 2002;277:14246-14254
36. Xu J, Song P, Miller ML, et al. Deletion of the chloride transporter Slc26a9 causes loss of tubulovesicles in parietal cells and impairs acid secretion in the stomach. Proc Natl Acad Sci USA 2008;105:17955-17960
37. Henquin JC, Nenquin M, Ravier MA, Szollosi A. Shortcomings of current models of glucose-induced insulin secretion. Diabetes Obes Metab 2009;11 (Suppl. 4):168-179
38. Majid A, Speake T, Best L, Brown PD. Expression of the Na+K+-2CI- cotransporter in alpha and beta cells isolated from the rat pancreas. Pflugers Arch 2001;442:570-576
39. Best L. Glucose-induced electrical activity in rat pancreatic beta-cells: dependence on intracellular chloride concentration. J Physiol 2005;568: 137-144
40. Alshahrani S, Di Fulvio M. Enhanced insulin secretion and improved glucose tolerance in mice with homozygous inactivation of the Na(+)K(+)2Cl (2) co-transporter 1. J Endocrinol 2012;215:59-70
41. Olivier AK, Yi Y, Sun X, et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest 2012;122:3755-3768
42. Anagnostopoulou P, Riederer B, Duerr J, et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 2012;122:3629-3634
43. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-783
44. Wei FY, Suzuki T, Watanabe S, et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest 2011;121:3598-3608
45. Laybutt DR, Preston AM, Akerfeldt MC, et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007;50:752-763
46. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-1898
47. Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008; 283:8723-8735
48. Loos RJ, Franks PW, Francis RW, et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007;56:1943-1947
49. Guo N, Parry EM, Li LS, et al. Short telomeres compromise β-cell signaling and survival. PLoS ONE 2011;6:e17858
50. Pascoe J, Hollern D, Stamateris R, et al. Free fatty acids block glucoseinduced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 2012;61:632-641
51. Saxena R, Elbers CC, Guo Y, et al.; Look AHEAD Research Group; DIAGRAM consortium. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci [corrected in Am J Hum Genet 2012;90:753]. Am J Hum Genet 2012;90:410-425
52. Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and nongenetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010;340:b4838